Pines Wealth Management LLC Invests $331,000 in Novo Nordisk A/S (NYSE:NVO)

Pines Wealth Management LLC bought a new position in Novo Nordisk A/S (NYSE:NVO - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 3,833 shares of the company's stock, valued at approximately $331,000.

A number of other institutional investors have also bought and sold shares of NVO. Novare Capital Management LLC raised its position in shares of Novo Nordisk A/S by 3.2% during the third quarter. Novare Capital Management LLC now owns 2,727 shares of the company's stock valued at $325,000 after buying an additional 85 shares during the last quarter. Steel Grove Capital Advisors LLC increased its holdings in Novo Nordisk A/S by 2.3% in the 2nd quarter. Steel Grove Capital Advisors LLC now owns 3,790 shares of the company's stock valued at $541,000 after acquiring an additional 86 shares during the last quarter. Benjamin Edwards Inc. increased its holdings in Novo Nordisk A/S by 2.6% in the 2nd quarter. Benjamin Edwards Inc. now owns 3,455 shares of the company's stock valued at $493,000 after acquiring an additional 87 shares during the last quarter. Rosenberg Matthew Hamilton lifted its stake in Novo Nordisk A/S by 2.5% in the 3rd quarter. Rosenberg Matthew Hamilton now owns 3,812 shares of the company's stock worth $454,000 after purchasing an additional 94 shares in the last quarter. Finally, Burns J W & Co. Inc. NY boosted its holdings in shares of Novo Nordisk A/S by 1.9% during the 3rd quarter. Burns J W & Co. Inc. NY now owns 5,430 shares of the company's stock valued at $647,000 after purchasing an additional 100 shares during the last quarter. Hedge funds and other institutional investors own 11.54% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts recently commented on NVO shares. BMO Capital Markets decreased their target price on Novo Nordisk A/S from $156.00 to $105.00 and set an "outperform" rating on the stock in a research report on Monday, December 23rd. Sanford C. Bernstein raised Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a report on Monday, January 6th. UBS Group upgraded Novo Nordisk A/S from a "sell" rating to a "buy" rating in a research report on Wednesday, January 8th. Cantor Fitzgerald restated an "overweight" rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. Finally, BNP Paribas upgraded shares of Novo Nordisk A/S to a "strong-buy" rating in a research report on Monday, December 2nd. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $140.20.

Novo Nordisk A/S Stock Up 0.4 %

Novo Nordisk A/S stock traded up $0.34 during midday trading on Thursday, hitting $83.26. 5,251,442 shares of the company's stock were exchanged, compared to its average volume of 7,963,100. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. The company has a market cap of $373.61 billion, a PE ratio of 26.94, a P/E/G ratio of 0.92 and a beta of 0.45. The firm has a 50-day moving average of $99.26 and a two-hundred day moving average of $118.18. Novo Nordisk A/S has a 12 month low of $80.05 and a 12 month high of $148.15.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.